The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorHelsinki University Central Hospital
About this trial
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Eligibility criteria
Qualifiers
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
ECOG performance status 0-2
Patients must have acceptable organ function as defined below. However, specific inclusion/
Disqualifiers
Absolute neutrophil count ≥ 1.5 x 109/l
Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
Platelets > 75 x 109/l (not applicable for hematological patients)
Total bilirubin < 1.5 x ULN
Trial design
Treatments tested in this trial
- Alectinib
- Cobimetinib
- Vismodegib
- Trastuzumab+Pertuzumab
- Entrectinib
- Atezolizumab
- Vemurafenib
- Regorafenib
- Apalutamide
- Abemaciclib
- Tepotinib
- Dabrafenib
- Trametinib
- Dabrafenib+Trametinib
- Pemigatinib
Treatment groups
250 Participants
are divided into 15 treatment groups15
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov